MHRA-100327-PIP01-21-M02 (update)

Key Facts

Active Substance
Active Substance:
  • SELPERCATINIB
Invented Name
  • Retsevmo
  • Retsevmo
  • Retevmo
PIP Number MHRA-100327-PIP01-21-M02 (update)
Pharmaceutical form(s)
  • Capsule, hard
  • Tablet
Therapeutic area
Therapeutic area:
  • Oncology
Conditions / Indications
Conditions / Indications:
  • Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms).
Route(s) of administration
Route(s) of administration:
  • Oral use
PIP applicant
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
Yes
Compliance Check Decision Date
Compliance opinion date
30/10/2025
Compliance Check Procedure Number
Compliance procedure number
MHRA-100327-PIP01-21-M02-C1

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):SELPERCATINIB.pdf
Published Date 01/05/2026